From CAPA to the Egyptian Drug Authority: Institutional History

1. Key takeaways

In 2019 Egypt consolidated its previously scattered pharmaceutical and medical device regulatory functions into a single body: the Egyptian Drug Authority (EDA). The legal basis is Law No. 151/2019, published in the Official Gazette No. 34 Bis (A) on August 25, 2019, whose Article 6 provides that the law enters into force on the day following the completion of 6 months from the date of publication. The EDA took over the registration- and licensing-related functions previously exercised by the National Organization for Drug Control and Research (NODCAR), the National Organization for Research and Control of Biologicals (NORCB), and the Central Administration of Pharmaceutical Affairs (CAPA) of the Ministry of Health. For companies, this history is not trivia: it determines which authority issued older certificates, how the current regulator derives its powers, and why every procedural pathway now runs through a single institutional entry point.

2. Legal basis

3. Expert insights

Insight 1: the publication date and the effective date are not the same day; six months lie between them.

Article 6 is drafted in two steps: the law is published in the Official Gazette, and it takes effect on the day following the completion of 6 months from publication. Counting from the publication date of August 25, 2019, entry into force falls in late February 2020. That buffer was designed to allow the new authority to be constituted and its implementing regulations to be issued. When companies cite historical documents they must therefore keep one point in mind: files issued during the transitional period between August 2019 and February 2020 rest on a different institutional foundation than those issued afterwards. A certificate signed by a predecessor body in that window may require a supplementary confirmation of continuity before the EDA accepts it.

Insight 2: the EDA is not a subordinate department of the Ministry of Health, but a public service body reporting directly to the Prime Minister.

The institutional description on the EDA website states that the EDA is a public service authority with legal personality affiliated to the Prime Minister. This matters greatly for understanding the intensity of its enforcement. The EDA holds independent licensing and enforcement powers, and it is responsible for customs release, establishment inspections, and the handling of violations, rather than functioning as a purely technical review unit. Practical implications follow: correspondence, commitments, and escalation requests should be addressed to the EDA as an autonomous regulator, and negotiation strategies modelled on dealing with a ministerial subdivision will misjudge the counterpart’s authority.

Insight 3: the three-in-one merger produces uniform standards, but also concentrates the review load.

Once the registration- and licensing-related functions of NODCAR (drug control and research), NORCB (biologicals research and control), and CAPA (pharmaceutical affairs) were merged into the EDA, registration, testing, inspection, and vigilance all landed in a single institution. The benefit is consistency of criteria across product categories. The cost is that all applications converge on one EDA entry point, which is precisely why queue times are relatively long in practice and why the fast track, which does not follow the ordinary waiting queue, carries real commercial value. Planning in this market means planning around the capacity of a single concentrated reviewer.

Insight 4: Article 1 of the law provides two sets of definitions at once, one for medical devices and one for medical technology.

Article 1 gives the medical device definition in definition item 3 (examined in detail in the dedicated article on definitions), and additionally defines 12 concepts in total, including medical technology, medical product, and biological products. The consequence is that in Egypt, devices share one statutory definitional framework with pharmaceuticals, biological products, cosmetics, disinfectants, and pesticides. For any borderline product, the determination must return to Article 1 rather than to custom or to the practice of other jurisdictions, because the same instrument governs all adjacent categories simultaneously.

4. Practical recommendations

1. Distinguish the publication date from the effective date when citing: describe the law as published on August 25, 2019, and describe entry into force according to the six-month rule of Article 6, so that no internal document mixes the two.
2. Position the EDA accurately in external communication: describe it as a public service body affiliated to the Prime Minister, never as a subordinate department of the Ministry of Health.
3. Check the issuing body of historical certificates first: documents issued before 2020 by CAPA and its peers must be confirmed for continuing validity under the EDA system before they are reused in new dossiers.
4. Plan the schedule around a single entry point: registration, import approval, changes, and vigilance all pass through the EDA, so timelines should be built on the load of that one institution.
5. Judge borderline products against Article 1: whenever a product touches the boundary between devices and pharmaceuticals or biological products, compare its intended use against the statutory definitions before choosing a pathway.

5. Verification checklist

• □ Recorded the publication date of the law as August 25, 2019
• □ Confirmed the entry-into-force rule under Article 6 (the day after 6 months from publication)
• □ Confirmed that the EDA replaced the relevant functions of NODCAR, NORCB, and CAPA
• □ Described the EDA externally as a public service body affiliated to the Prime Minister
• □ Checked the issuing body and continuing validity of historical documents
• □ Compared borderline products against the definition items of Article 1

Regulatory information verified as of October 29, 2026. The institutional history and entry-into-force mechanism described in this article are subject to the official text of Law No. 151/2019 and to the current content of the institutional description on the EDA website.

• Local Egypt support: GRZAN assists manufacturers from the Chinese mainland and overseas with medical device registration, import approval, and change applications before the Egyptian Drug Authority (EDA), including design of the registration applicant structure (importing company, local factory, or scientific office), preparation for Scientific Committee evaluation, advisory work on pathways for obtaining free sale certificates from reference countries, Arabic localization of labels and instructions for use, and the build-out of vigilance systems and periodic reporting.
• Service capabilities: product characterization and risk classification (devices Class I–III and IVDs Class A–D), registration and re-registration, determination of applicability of system registration and group registration, three-category determination of changes, import approval and annual import plans, and support for vigilance reports and field safety corrective actions.
• Contact: hito.lin@grzan.cn; website www.grzan.cn.